Sequencing current therapies in the treatment of metastatic prostate cancer

Cancer Treatment Reviews
Loana B ValencaMark M Pomerantz

Abstract

The standard treatment for metastatic prostate cancer is androgen deprivation therapy. However, progressive, metastatic disease usually develops, giving rise to metastatic castration-resistant prostate cancer (mCRPC). Great improvements have been made recently in the management of mCRPC, with current approved treatments including chemotherapy, androgen receptor-targeted agents, immunotherapies and radiopharmaceuticals. While the emergence of multiple effective therapies is encouraging, devising a treatment strategy can be difficult and it is becoming increasingly important, and challenging, to identify factors that influence the ideal timing of specific therapies. Considering where to place these agents in the treatment schedule of mCRPC, or whether these agents should be sequenced or combined to derive the optimal benefit for the patient, is not yet clear. Furthermore, cross-resistance may exist between these agents, which may ultimately influence treatment decisions and sequence choices. Preliminary data are emerging regarding the safety and activity for sequential treatment regimens, but there are currently no prospective studies. As prostate cancer is highly heterogeneous clinically, it is likely that no single treatment se...Continue Reading

References

Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Nov 1, 1981·The Journal of Cell Biology·J Parness, S B Horwitz
Jul 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·P RougierH Bleiberg
Oct 8, 1998·The New England Journal of Medicine·M A EisenbergerB A Lowe
Nov 22, 2001·Journal of the National Cancer Institute·M E GrossmannD J Tindall
Apr 11, 2003·The Journal of Urology·Wassim KassoufArmen G Aprikian
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James L MohlerFrank S French
Oct 8, 2004·The New England Journal of Medicine·Ian F TannockUNKNOWN TAX 327 Investigators
Oct 8, 2004·The New England Journal of Medicine·Daniel P PetrylakE David Crawford
May 11, 2005·Clinical Prostate Cancer·Laurence Klotz, Paul Schellhammer
Jul 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bernhard J C EiglMartin E Gleave
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I Scher, Charles L Sawyers
Apr 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Andrew LoblawUNKNOWN American Society of Clinical Oncology
Sep 3, 2010·Cancer Research·Meng-Lei ZhuNatasha Kyprianou
Sep 8, 2010·The New England Journal of Medicine·Philip W KantoffUNKNOWN IMPACT Study Investigators
Mar 5, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gerhardt AttardJohann S de Bono
Oct 1, 2011·Clinical Genitourinary Cancer·Mari NakabayashiMary-Ellen Taplin
Jul 10, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MezynskiJ de Bono
Aug 17, 2012·The New England Journal of Medicine·Howard I ScherUNKNOWN AFFIRM Investigators
Sep 19, 2012·Cancer Research·Maria Thadani-MuleroParaskevi Giannakakou
Jan 12, 2013·The Lancet Oncology·Christopher Sweeney
Apr 12, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y LoriotC Massard
Apr 16, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K L NoonanK N Chi
May 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M AparicioChristopher J Logothetis

❮ Previous
Next ❯

Citations

Feb 2, 2016·Life Sciences·Jasmina MakarevićRoman A Blaheta
Mar 29, 2016·Prostate Cancer·Mingzhe LiuGuangdong Yang
Oct 23, 2016·Drug Discovery Today. Technologies·Ester Fernandez-SalasArul M Chinnaiyan
Aug 6, 2016·International Journal of Pharmaceutics·Kathleen A FitzgeraldCaitriona M O' Driscoll
Dec 18, 2016·International Urology and Nephrology·Jieping Hu, Qingke Chen
Feb 19, 2017·Endocrine-related Cancer·Alyson MurrayMichael J Duffy
Jun 2, 2017·Endocrine-related Cancer·Sangeeta KumariHannelore V Heemers
Sep 29, 2015·EMBO Molecular Medicine·Suzan StellooWilbert Zwart
Nov 30, 2019·Oxidative Medicine and Cellular Longevity·Masoud AkbariAlp Sener
Feb 24, 2017·Current Oncology Reports·Mary NakazawaNatasha Kyprianou
Apr 29, 2021·Expert Opinion on Drug Discovery· FaheemSankaranarayanan Murugesan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.